Company Overview and News
By Eric Bush, CFA - Gavekal Capital BlogOur GKCI Emerging Markets Index broke down to its lowest level since July 2009. The index is already off 25% from the 20
(click to enlarge)A recent Neuberger Berman analysis, by Conrad A. Saldanha, makes the case that the emerging markets as an asset class have hit their bottom an
By Tim MaverickThere's one piece of market-related data that I check faithfully - and I believe all serious investors should do the same.It's the monthly survey of fund managers from around the world,
With the S&P 500 just barely hanging on to gains in 2015, a lot of investors would tell you that it hasn't been a great year for stocks. On a comparative basis, though, the US is holding up extrem
Emerging market (EM) stocks and currencies have posted volatile and disappointing performance this year amid concerns about slowing global growth and lower commodity prices. One investing surp
Editor's note: This article was originally published on December 26, 2015 by Carlos Arteta, M. Ayhan Kose, Franziska Ohnsorge, Marc Stocker, and Lei Sandy Ye here.In a widely anticipated move, on Dece
For several months now, global markets and policymakers have waited for the FOMC's periodic meetings nervously. The central bank of the world's largest economy is preparing to raise interest rates fro
By Alliance BernsteinEmerging-market (EM) stocks are headed for their third straight down year, and valuations are now quite cheap versus developed-market (DM) stocks. We think 2016 co
Editor's note: This article was originally published on December 15, 2015 here.Today, we are fortunate to have a guest post written by Eric Fischer, PhD candidate at the University of California, Sant
Calls for International coordination of macroeconomic policy are back, after a 30-year hiatus. To some it looks anomalous that the Fed is about to raise interest rates at a time when most major centra
By WisdomTreeEmerging market (EM) equities have been shrouded by years of underperformance. China's transition from an investment-led economy supporting commodity prices and the performance of
By Valentin SchmidCan an economist be a celebrity? Usually not.There are a few exceptions and Carmen Reinhart is one. Certainly after her book This Time Is Different, came out in 2009.Carmen Reinhart
Original postBy Stuart BurnsPart of the reason China's economy has slowed is as a result of deliberate policy actions taken by Beijing to steer it from investment-led, export-orientated manufacturing
It seems as if in every client meeting lately, I'm getting questions about emerging market (EM) stocks. Many investors are looking for that magic bottom and are wondering if it's time to step
By Tim MaverickIf there's one truism I've found during my years in the investing field - which date back to the 1980s - it's the fact that everything is cyclical.What runs hot will inevitably turn col
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...